Effect of EPC-K1 on myocardial infarct size in a rat model with coronary artery occlusion and reperfusion.
1. The ability of EPC-K1 to improve myocardial infarction was evaluated in a rat model with coronary artery occlusion and reperfusion. 2. The myocardial infarct size was 30.5 +/- 1.7% by intravenous (i.v.) administration and 28.8 +/- 2.7% by intraduodenal (i.d.) administration of the saline EPC-K1 at doses between 1 and 10 mg/kg, i.v. and at doses between 50 and 200 mg/kg, i.d., reduced myocardial infarct size dose dependently. Significant reduction in myocardial infarct size was found at a dose of 10 mg/kg, i.v., and 200 mg/kg, i.d.
Yamada
S
S
Nihon Bioresearch Center Inc., Gifu, Japan.
Yashita
T
T
Yamaguchi
K
K
Kyuki
K
K
Sakaue
T
T
Ogata
K
K
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001205:Ascorbic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy*; D004195:Disease Models, Animal; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D015428:Myocardial Reperfusion Injury; D051381:Rats; D017208:Rats, Wistar; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000975:Antioxidants; D016166:Free Radical Scavengers; D014810:Vitamin E; C066638:potassium ascorbyl tocopheryl phosphate; D001205:Ascorbic Acid